Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBIT Margin: 2016-2025

Historic EBIT Margin for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to -106.85%.

  • Ultragenyx Pharmaceutical's EBIT Margin fell 1223.00% to -106.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -86.27%, marking a year-over-year increase of 1622.00%. This contributed to the annual value of -95.67% for FY2024, which is 3541.00% up from last year.
  • Ultragenyx Pharmaceutical's EBIT Margin amounted to -106.85% in Q3 2025, which was down 64.90% from -64.80% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's EBIT Margin's 5-year high stood at -64.80% during Q2 2025, with a 5-year trough of -248.14% in Q3 2022.
  • Its 3-year average for EBIT Margin is -109.81%, with a median of -102.62% in 2025.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's EBIT Margin soared by 22,511bps in 2021, and later slumped by 13,812bps in 2022.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's EBIT Margin stood at -122.99% in 2021, then crashed by 1,792bps to -140.91% in 2022, then skyrocketed by 4,510bps to -95.81% in 2023, then skyrocketed by 2,164bps to -74.16% in 2024, then crashed by 1,223bps to -106.85% in 2025.
  • Its EBIT Margin stands at -106.85% for Q3 2025, versus -64.80% for Q2 2025 and -102.62% for Q1 2025.